urea has been researched along with Lupus Erythematosus, Systemic in 47 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 15-year-old boy with epilepsy and cerebral calcifications, treated with valproic acid, ethyl phenylbarbiturate and ethosuximide, was referred for drug induced systemic lupus erythematosus." | 7.71 | Latent coeliac disease in a child with epilepsy, cerebral calcifications, drug-induced systemic lupus erythematosus and intestinal folic acid malabsorption associated with impairment of folic acid transport across the blood-brain barrier. ( Calvani, M; Guaitolini, C; Paolone, G; Parisi, G; Parisi, P, 2001) |
| "A 15-year-old boy with epilepsy and cerebral calcifications, treated with valproic acid, ethyl phenylbarbiturate and ethosuximide, was referred for drug induced systemic lupus erythematosus." | 3.71 | Latent coeliac disease in a child with epilepsy, cerebral calcifications, drug-induced systemic lupus erythematosus and intestinal folic acid malabsorption associated with impairment of folic acid transport across the blood-brain barrier. ( Calvani, M; Guaitolini, C; Paolone, G; Parisi, G; Parisi, P, 2001) |
| "Sera from 76 patients with diverse vasculitis, systemic lupus erythematosus (SLE) and hydralazine-induced lupus (HiL) were analysed by ELISA for their reactivity with native, reduced or urea-denatured MPO, respectively, as well as with bacterially expressed heavy and light subunits of MPO." | 3.68 | Antineutrophil cytoplasmic autoantibodies (ANCA) recognizing a recombinant myeloperoxidase subunit. ( Bautz, EK; Bautz, FA; Bleil, L; Kalden, JR; Pedrollo, E, 1993) |
| " Regular testing of urine and bloodm and detailed postmortem examinations showed (a) that with increasing drug dose levels heavy proteinuria was almost eliminated and blood urea concentrations significantly lowered; (b) that in treated and untreated mice moderate to severe anaemia developed, apparently unrelated to the degree of uraemia; (c) that changes in renal function did not correlate with antinuclear antibody activity, nor did the drop in packed cell volume correlate with fixed or free circulating antierythrocyte autoantibody positivity; (d) that histological analysis of renal changes showed that at the highest dose level glomerular lesions were minimal." | 3.66 | Thiamphenicol and lupus nephritis. The effects of long-term therapy on kidney function and pathology: a pilot study. ( Aarons, I; Howie, JB; Simpson, LO, 1979) |
| "In several cases with IgA nephropathy (IgAN), differential diagnosis is difficult due to the complication with other systemic diseases which can induce secondary IgAN." | 1.62 | Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy. ( Fukao, Y; Kano, T; Kato, R; Lee, M; Makita, Y; Nakayama, M; Suzuki, H; Suzuki, Y, 2021) |
| "In conclusion, IFN-beta treatment of lupus nephritis in MRL-Fas(lpr) mice is remarkably beneficial and suggests that IFN-beta may be an appealing therapeutic candidate for subtypes of human lupus." | 1.33 | Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. ( Brenner, W; Galle, PR; Hansen, T; Kelley, VR; Menke, J; Paul, K; Relle, M; Schwarting, A; Tschirner, S, 2005) |
| "Sera from 30 patients with systemic lupus erythematosus (SLE), but without features of anti-phospholipid syndrome (APS) (SLE/non APS), six with SLE and secondary APS, (SLE/APS) and 11 with primary APS (PAPS) were also evaluated as controls." | 1.30 | Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. ( Kordossis, T; Moutsopoulos, HM; Petrovas, C; Vlachoyiannopoulos, PG, 1999) |
| "Thiamphenicol at the rate of 50 mg/kg/day given to female NZBxOUW F1 hybrid mice from weaning and continuing throughout life resulted in a considerable extension of lifespan, although this was less than in mice given the same drug dosage from first antinuclear antibody (ANA) positivity (Simpson, Aarons and Howie, 1979)." | 1.26 | Thiamphenicol and lupus nephritis. II. The effects of giving the drug from weaning to NZBxOUW F1 hybrid female mice. ( Aarons, I; Howie, JB; Simpson, LO, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 32 (68.09) | 18.7374 |
| 1990's | 3 (6.38) | 18.2507 |
| 2000's | 6 (12.77) | 29.6817 |
| 2010's | 5 (10.64) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, M | 1 |
| Suzuki, H | 1 |
| Kato, R | 1 |
| Fukao, Y | 1 |
| Nakayama, M | 2 |
| Kano, T | 1 |
| Makita, Y | 1 |
| Suzuki, Y | 1 |
| Khorasani, S | 1 |
| Mahmoudi, M | 1 |
| Kalantari, MR | 1 |
| Lavi Arab, F | 1 |
| Esmaeili, SA | 1 |
| Mardani, F | 1 |
| Tabasi, N | 1 |
| Rastin, M | 1 |
| Tripathy, R | 1 |
| Panda, AK | 1 |
| Das, BK | 1 |
| Bhimani, JP | 1 |
| Ouseph, R | 1 |
| Ward, RA | 1 |
| Miyano, A | 1 |
| Yang, Z | 1 |
| Liang, Y | 1 |
| Li, C | 1 |
| Xi, W | 1 |
| Zhong, R | 1 |
| Ho, CY | 1 |
| Wong, CK | 1 |
| Li, EK | 1 |
| Tam, LS | 1 |
| Lam, CW | 1 |
| PERLMUTTER, M | 1 |
| GROSSMAN, SL | 1 |
| ROTHENBERG, S | 1 |
| DOBKIN, G | 1 |
| POLLAK, VE | 2 |
| PIRANI, CL | 1 |
| SCHWARTZ, FD | 1 |
| Schwarting, A | 1 |
| Paul, K | 1 |
| Tschirner, S | 1 |
| Menke, J | 1 |
| Hansen, T | 1 |
| Brenner, W | 1 |
| Kelley, VR | 1 |
| Relle, M | 1 |
| Galle, PR | 1 |
| Pedrollo, E | 1 |
| Bleil, L | 1 |
| Bautz, FA | 1 |
| Kalden, JR | 1 |
| Bautz, EK | 1 |
| Matteucci, E | 1 |
| Migliorini, P | 1 |
| Bertoni, C | 1 |
| Dolcher, MP | 1 |
| Marchini, B | 1 |
| Giampietro, O | 1 |
| Petrovas, C | 1 |
| Vlachoyiannopoulos, PG | 1 |
| Kordossis, T | 1 |
| Moutsopoulos, HM | 1 |
| Al-Maini, MH | 1 |
| Mountz, JD | 1 |
| Al-Mohri, HA | 1 |
| El-Ageb, EM | 1 |
| Al-Riyami, BM | 1 |
| Svenson, KL | 1 |
| Zhou, T | 1 |
| Richens, ER | 1 |
| Calvani, M | 1 |
| Parisi, P | 1 |
| Guaitolini, C | 1 |
| Parisi, G | 1 |
| Paolone, G | 1 |
| Asanuma, Y | 1 |
| Nagai, K | 1 |
| Kato, M | 1 |
| Sugiura, H | 1 |
| Kawai, S | 1 |
| Rahman, ZS | 1 |
| Tin, SK | 1 |
| Buenaventura, PN | 1 |
| Ho, CH | 1 |
| Yap, EP | 1 |
| Yong, RY | 1 |
| Koh, DR | 1 |
| Srivastava, RN | 1 |
| Mayekar, G | 1 |
| Anand, R | 1 |
| Choudhry, VP | 1 |
| Ghai, OP | 1 |
| Tandon, HD | 1 |
| Simpson, LO | 2 |
| Aarons, I | 2 |
| Howie, JB | 2 |
| Hill, GS | 1 |
| Hinglais, N | 1 |
| Tron, F | 1 |
| Bach, JF | 1 |
| Giordano, C | 1 |
| Pluvio, M | 1 |
| Esposito, R | 1 |
| Brennan, FM | 1 |
| Williams, DG | 1 |
| Bovill, D | 1 |
| Stocks, MR | 1 |
| Maini, RN | 1 |
| Ben Ammar, S | 1 |
| Ben Abdallah, T | 1 |
| Beikahia, C | 1 |
| el-Matri, A | 1 |
| Ben Ayed, H | 1 |
| Whittingham, S | 1 |
| Mackay, IR | 3 |
| Casey, TP | 3 |
| Robson, G | 1 |
| Chan, D | 1 |
| Beare, JM | 1 |
| Forbes, MJ | 1 |
| Sinclair, L | 1 |
| Kahn, S | 1 |
| Sagel, J | 1 |
| Eales, L | 1 |
| Rabkin, R | 1 |
| Scott, DG | 1 |
| Rowell, NR | 1 |
| Feng, PH | 2 |
| Jayaratnam, FJ | 1 |
| Tock, EP | 1 |
| Seah, CS | 1 |
| Seedat, YK | 1 |
| Cheah, PS | 1 |
| Lee, YK | 1 |
| Nanra, RS | 1 |
| Kincaid-Smith, P | 1 |
| Wilkinson, JH | 1 |
| Dorfmann, H | 1 |
| Kahn, MF | 1 |
| de Sèze, S | 1 |
| Jansson, E | 1 |
| Vainio, U | 1 |
| Tuuri, S | 1 |
| Nolph, KD | 1 |
| Stoltz, ML | 1 |
| Maher, JF | 1 |
| Nakata, Y | 1 |
| Onishi, T | 1 |
| Arimori, S | 1 |
| Lennon, PA | 1 |
| Adam, WR | 1 |
| Bladin, P | 1 |
| Coote, BD | 1 |
| Dawborn, JK | 1 |
| Greer, CH | 1 |
| Diessner, GR | 1 |
| Howard, FM | 1 |
| Winkelmann, RK | 1 |
| Lambert, EH | 1 |
| Mulder, DW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect Of Dialysate Flow Rate On Mass Transfer Coefficient - Area (KoA) In Dialyzers With Different Membrane Packing Densities[NCT00636077] | 12 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| A Multinational Prospective Study on the Duration of Steroid Therapy in Steroid Sensitive Nephrotic Syndrome[NCT03878914] | Phase 4 | 34 participants (Actual) | Interventional | 2019-08-06 | Terminated (stopped due to The study was terminated at all but one site because of the pandemic) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00636077)
Timeframe: During the third treatment with each dialyzer (one time during each trial period week)
| Intervention | KoA for b2-microglobulin (mL/min) (Mean) | ||
|---|---|---|---|
| 350 mL/min Dialysate Flow Rate | 500 mL/min Dialysate Flow Rate | 800 mL/min Dialysate Flow Rate | |
| F160NR | 27 | 28 | 31 |
| F200NR | 27 | 25 | 21 |
| HD-C4 Big | 65 | 62 | 64 |
| HD-C4 Small | 61 | 57 | 56 |
(NCT00636077)
Timeframe: During the third treatment with each dialyzer (one time during each trial period week)
| Intervention | KoA for Phosphorus (mL/min) (Mean) | ||
|---|---|---|---|
| 350 mL/min Dialysate Flow Rate | 500 mL/min Dialysate Flow Rate | 800 mL/min Dialysate Flow Rate | |
| F160NR | 434 | 450 | 458 |
| F200NR | 504 | 491 | 560 |
| HD-C4 Big | 434 | 435 | 520 |
| HD-C4 Small | 334 | 422 | 415 |
KoA is a constant that describes the efficiency of a dialyzer in removing urea. KoA is determined by surface area of the membrane, the thickness of the membrane and pore size. (NCT00636077)
Timeframe: During the third treatment with each dialyzer (one time during each trial period week)
| Intervention | KoA for urea (mL/min) (Mean) | ||
|---|---|---|---|
| 350 mL/min Dialysate Flow Rate | 500 mL/min Dialysate Flow Rate | 800 mL/min Dialysate Flow Rate | |
| F160NR | 770 | 738 | 809 |
| F200NR | 798 | 890 | 817 |
| HD-C4 Big | 844 | 898 | 922 |
| HD-C4 Small | 763 | 748 | 761 |
(NCT00636077)
Timeframe: During the third treatment with each dialyzer (one time during each trial period week)
| Intervention | whole blood clearance B2-microglobulin (Mean) | ||
|---|---|---|---|
| 350 mL/min Dialysate Flow Rate | 500 mL/min Dialysate Flow Rate | 800 mL/min Dialysate Flow Rate | |
| F160NR | 87 | 86 | 78 |
| F200NR | 72 | 65 | 75 |
| HD-C4 Big | 106 | 129 | 118 |
| HD-C4 Small | 119 | 118 | 121 |
(NCT00636077)
Timeframe: During the third treatment with each dialyzer (one time during each trial period week)
| Intervention | whole blood phosphorus clearance mL/min (Mean) | ||
|---|---|---|---|
| 350 mL/min Dialysate Flow Rate | 500 mL/min Dialysate Flow Rate | 800 mL/min Dialysate Flow Rate | |
| F160NR | 247 | 260 | 272 |
| F200NR | 249 | 265 | 281 |
| HD-C4 Big | 255 | 269 | 286 |
| HD-C4 Small | 252 | 261 | 273 |
(NCT00636077)
Timeframe: During the third treatment with each dialyzer (one time during each trial period week)
| Intervention | Whole blood urea clearance (mL/min) (Mean) | ||
|---|---|---|---|
| 350 mL/min Dialysate Flow Rate | 500 mL/min Dialysate Flow Rate | 800 mL/min Dialysate Flow Rate | |
| F160NR | 271 | 293 | 313 |
| F200NR | 274 | 313 | 327 |
| HD-C4 Big | 279 | 315 | 340 |
| HD-C4 Small | 270 | 295 | 320 |
2 reviews available for urea and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Advances in the treatment of diseases of the skin.
Topics: Acne Vulgaris; Alopecia Areata; Dermatitis, Contact; Humans; Lupus Erythematosus, Systemic; Lymphati | 1971 |
Diagnostic significance of enzyme determinations in urine.
Topics: Acute Disease; Alkaline Phosphatase; Chronic Disease; Clinical Enzyme Tests; Cysts; Diabetes Mellitu | 1968 |
45 other studies available for urea and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy.
Topics: Adult; Antibodies, Monoclonal; Antiviral Agents; Arthritis, Rheumatoid; Crohn Disease; Diagnosis, Di | 2021 |
Amelioration of regulatory T cells by Lactobacillus delbrueckii and Lactobacillus rhamnosus in pristane-induced lupus mice model.
Topics: Animals; Anti-Inflammatory Agents; Antibodies; Cell Proliferation; Creatinine; Cytokines; Disease Mo | 2019 |
Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE.
Topics: Adult; Antibodies, Antinuclear; Case-Control Studies; Complement C3; Complement C4; Creatinine; DNA; | 2015 |
Effect of increasing dialysate flow rate on diffusive mass transfer of urea, phosphate and beta2-microglobulin during clinical haemodialysis.
Topics: beta 2-Microglobulin; Cross-Over Studies; Dialysis Solutions; Female; Glomerulonephritis; Humans; Hy | 2010 |
[Study of anti-SSA 52-kDa and anti-SSA 60-kDa avidity antibodies in pregnant women].
Topics: Antibodies, Antinuclear; Antibody Affinity; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female; F | 2011 |
Associations of serum urea, creatinine and uric acid with clinical and laboratory features in patients with systemic lupus erythematosus.
Topics: Arthritis; Biomarkers; China; Comorbidity; Creatinine; Exanthema; Female; Humans; Logistic Models; L | 2012 |
Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Biomarkers; Case-Control Studies; Creatinine; Female; Glomerulonephritis; Humans; Lupus | 2003 |
Urineserum urea nitrogen ratio; simple test of renal function in acute azotemia and oliguria.
Topics: Anuria; Azotemia; Humans; Kidney Function Tests; Lupus Erythematosus, Systemic; Nitrogen; Oliguria; | 1959 |
THE NATURAL HISTORY OF THE RENAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS.
Topics: Arteries; Black People; Blood Chemical Analysis; Creatine; Creatinine; Glomerulonephritis; Kidney Di | 1964 |
TREATMENT OF THE NEPHRITIS OF SYSTEMIC LUPUS ERYTHEMATOSUS.
Topics: Biopsy; Blood Chemical Analysis; Diagnosis, Differential; Glomerulonephritis; Humans; Kidney Functio | 1964 |
Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.
Topics: Animals; Cell Division; Disease Models, Animal; Disease Progression; Flow Cytometry; Immunoglobulin | 2005 |
Antineutrophil cytoplasmic autoantibodies (ANCA) recognizing a recombinant myeloperoxidase subunit.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antibody Specificity; Autoantibodies; Enzyme-Linked Immunoso | 1993 |
An early diagnosis of kidney involvement in immunologically-mediated multisystem diseases.
Topics: Adult; Blood Pressure Determination; Case-Control Studies; Creatinine; Cryoglobulinemia; Female; Hum | 1996 |
Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.
Topics: Adult; Anti-HIV Agents; Antibodies, Anticardiolipin; Antibody Affinity; Antibody Specificity; Antiph | 1999 |
Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus.
Topics: Adolescent; Adult; Alanine Transaminase; Apoptosis; Arabs; Aspartate Aminotransferases; Biomarkers; | 2000 |
Latent coeliac disease in a child with epilepsy, cerebral calcifications, drug-induced systemic lupus erythematosus and intestinal folic acid malabsorption associated with impairment of folic acid transport across the blood-brain barrier.
Topics: Adolescent; Anticonvulsants; Biological Transport; Blood-Brain Barrier; Brain; Brain Diseases; Calci | 2001 |
Weekly pulse therapy of methotrexate improves survival compared with its daily administration in MRL/lpr mice.
Topics: Animals; Antirheumatic Agents; Autoantibodies; Autoimmunity; Blood Cell Count; Body Weight; Glomerul | 2002 |
A novel susceptibility locus on chromosome 2 in the (New Zealand Black x New Zealand White)F1 hybrid mouse model of systemic lupus erythematosus.
Topics: Alleles; Animals; Autoantibodies; Chromosome Mapping; Crosses, Genetic; Disease Models, Animal; Fema | 2002 |
Nephrotic syndrome in indian children.
Topics: Adolescent; Age Factors; Amyloidosis; Child; Child, Preschool; Edema; Female; Glomerulonephritis; He | 1975 |
Thiamphenicol and lupus nephritis. The effects of long-term therapy on kidney function and pathology: a pilot study.
Topics: Animals; Antibodies, Antinuclear; Body Weight; Female; Glomerulonephritis; Immune Complex Diseases; | 1979 |
Thiamphenicol and lupus nephritis. II. The effects of giving the drug from weaning to NZBxOUW F1 hybrid female mice.
Topics: Animals; Antibodies, Antinuclear; Dose-Response Relationship, Drug; Female; Glomerulonephritis; Hema | 1979 |
Systemic lupus erythematosus. Morphologic correlations with immunologic and clinical data at the time of biopsy.
Topics: Adult; Antibodies; Antibodies, Antinuclear; Antigen-Antibody Reactions; B-Lymphocytes; Complement Sy | 1978 |
Urea index and nitrogen balance in uremic patients on miminal nitrogen intakes.
Topics: Adolescent; Adult; Amino Acids, Essential; Child; Female; Humans; Lupus Erythematosus, Systemic; Nit | 1975 |
Administration of monoclonal anti-Sm antibody prolongs the survival and renal function of MRL-lpr/lpr mice.
Topics: Animals; Antibodies, Antinuclear; Antibodies, Monoclonal; Antibody Specificity; Antigen-Antibody Com | 1986 |
[A discordance between urea and creatinine figures. Apropos of several patients].
Topics: Adult; Creatinine; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Lupus Erythematosus, Sys | 1987 |
Systemic lupus erythematosus induced by procaine amide.
Topics: Aged; Antibodies, Antinuclear; Arrhythmias, Cardiac; Blood Proteins; Blood Sedimentation; Humans; Im | 1970 |
Azathioprine in systemic lupus erythematosus.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Age Factors; Antimetabolites; Azathioprine; Humans; K | 1973 |
Chronic lupus erythematosus: observations on long-term survivors of "suppressive" therapy of lupus nephritis with prednisolone.
Topics: Antibodies, Antinuclear; Biopsy; Female; gamma-Globulins; Humans; Kidney; Lupus Erythematosus, Syste | 1973 |
Immunosuppression by cyclophosphamide in NZB X NZW mice with lupus nephritis.
Topics: Albuminuria; Animals; Autoantibodies; Autoimmune Diseases; Blood Cell Count; Carcinogens; Coombs Tes | 1968 |
Prednisolone treatment of lupus nephritis: Effect of high doses on course of disease, renal function, histological lesions, and immunological reactions.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Biopsy; Blood Pressure; Blood Sedimentation; Complement | 1970 |
Lupus nephritis: response to azathioprine.
Topics: Adolescent; Azathioprine; Edema; Female; Glomerular Filtration Rate; Glomerulonephritis; Hematuria; | 1974 |
Azathioprine administration to NZB X NZW hybrid mice with lupus nephritis: beneficial effect complicated by development of malignant lymphomas.
Topics: Animals; Autoantibodies; Autoimmune Diseases; Azathioprine; Body Weight; Female; Hodgkin Disease; Ki | 1973 |
The significance of serum creatinine and the blood urea-serum creatinine ratio in azotaemia.
Topics: Acute Disease; Acute Kidney Injury; Adult; Chronic Disease; Creatinine; Diet Therapy; Dietary Protei | 1972 |
Immunohistological studies of the kidney in systemic lupus erythematosus and systemic sclerosis using antisera to IgG, C3, fibrin, and human renal glomeruli.
Topics: Adult; Albuminuria; Basement Membrane; Blood Pressure; Capillaries; Complement System Proteins; Crea | 1974 |
Cyclophosphamide in treatment of systemic lupus erythematosus: 7 years' experience.
Topics: Administration, Oral; Adolescent; Adult; Amenorrhea; Blood Cell Count; Cyclophosphamide; Female; Hem | 1973 |
Treatment of systemic lupus erythematosus with renal insufficiency.
Topics: Adolescent; Albuminuria; Blood Cell Count; Cyclophosphamide; Female; Glomerular Filtration Rate; Hum | 1973 |
Mortality in systemic lupus erythematosus: a 10-year review.
Topics: Adolescent; Adult; Aged; Bronchopneumonia; Cerebrospinal Fluid Proteins; Child; Chlorides; Coma; Cyc | 1973 |
Lupus nephritis: clinical course in relation to treatment.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Creatinine; Cyclophosphamide; Female; Follow-Up Studie | 1973 |
[Possible iatrogenic lupus induced by phenturide (apropos of 2 cases)].
Topics: Adolescent; Adult; Albuminuria; Arthritis; Endocarditis, Bacterial; Female; Humans; Iatrogenic Disea | 1972 |
Cultivation of a mycoplasma from the bone marrow in systemic lupus erythematosus disseminatus.
Topics: Adult; Animals; Arginine; Bone Marrow; Culture Media; Female; Glucose; Humans; Immune Sera; Lupus Er | 1971 |
Altered peritoneal permeability in patients with systemic vasculitis.
Topics: Capillary Permeability; Creatinine; Diabetic Angiopathies; Diffusion; Epithelium; Humans; Hypertensi | 1971 |
[Modifications of anti-muscle membrane antibody by varying solubilization of muscle membrane and the effect of dilution of antigen and patient's sera].
Topics: Animals; Antibodies; Antigens; Bile Acids and Salts; Humans; Immune Sera; Immunoelectrophoresis; Lup | 1971 |
Transient blindness associated with renal failure.
Topics: Adult; Aged; Blindness; Body Weight; Brain Edema; Creatinine; Electroencephalography; Female; Hemogl | 1971 |
Systemic lupus erythematosus in NZB x NZW hybrid mice treated with the corticosteroid drug betamethasone.
Topics: Antibody Formation; Autoantibodies; Betamethasone; Body Weight; Glycosuria; Hybridization, Genetic; | 1968 |
Laboratory tests in polymyositis.
Topics: 17-Ketosteroids; Adult; Aspartate Aminotransferases; Blood; Blood Cell Count; Blood Protein Electrop | 1966 |